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DHA–paclitaxel is a conjugate of paclitaxel and the fatty acid, docosahexaenoic acid. Preclinical studies have demonstrated increased
activity, relative to paclitaxel, with the potential for an improved therapeutic ratio. We conducted a phase I study to determine the
maximum tolerated doses of DHA–paclitaxel and carboplatin when administered in combination. Two cohorts of patients were
treated: carboplatin AUC 5 with DHA–paclitaxel 660mgm
 2 and carboplatin AUC 5 with DHA–paclitaxel 880mgm
 2. Both drugs
were given on day 1 every 21 days. A total of 15 patients were enrolled with a median age of 59 years (range 33–71). All patients
had advanced cancer refractory to standard treatment, performance status 0–2 and were without major organ dysfunction. A total of
54 cycles of treatment were delivered. No dose-limiting toxicity (DLT) was seen in the first cohort of three patients. In an expanded
second cohort, neutropenia was the main DLT, occurring in the first cycle of treatment in five of 12 patients: three of these patients
and one additional patient also experienced dose-limiting grade 3 transient rises in liver transaminases. No alopecia was seen and one
patient developed clinically significant neuropathy. One partial response was seen in a patient with advanced adenocarcinoma of the
oesophago-gastric junction and 12 patients had stable disease with a median time to progression of 184 days (range 60–506 days).
The recommended phase II dose in pretreated patients is Carboplatin AUC 5 and DHA–paclitaxel 660mgm
 2 given every 21 days.
Further studies with Carboplatin AUC 5 and DHA-paclitaxel 880mgm
 2, given every 28 days, are warranted in chemo-naive
patients.
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Paclitaxel is an effective and widely used anticancer drug with
activity, either alone or in combination, against a range of solid
tumours including breast, lung, urothelial and ovarian malignan-
cies (Rowinsky and Donehower, 1995). Toxicities associated with
paclitaxel, and the other commonly used taxane docetaxel, include
hypersensitivity reactions, alopecia and myelosuppression. Pacli-
taxel can also cause significant peripheral neuropathy. Conse-
quently, there is much interest in the development of new taxanes
or taxane analogues with improved efficacy and less toxicity.
One approach to improve upon the therapeutic index of
chemotherapy drugs is conjugation to fatty acids. In preclinical
models, data indicate preferential uptake of such conjugates into
tumours compared to normal tissue (Bradley et al, 2001b). Once in
the cell, normal metabolism cleaves the fatty acid moiety to yield
the active drug. Conjugation with a fatty acid would be expected to
change the pharmacokinetic profile of the drug, possibly allowing
for prolonged exposure of tumour cells to the chemotherapeutic
agent and a reduction in the peak drug concentration, which might
alter the toxicity profile.
DHA–paclitaxel is a covalent conjugate of paclitaxel and the
essential fatty acid, docosahexaenoic acid (DHA) (Figure 1).
Docosahexaenoic acid is an omega-3, natural fatty acid, and a
normal component of human breast milk. Bradley and co-workers
have reported the preclinical activity, animal toxicity and
pharmacokinetics of DHA–paclitaxel as follows.
The conjugate itself was found to have little in vitro cytotoxic
activity. DHA–paclitaxel was found to be approximately 1000
times less active than paclitaxel against a panel of tumour cell lines.
In contrast, studies in human xenograft tumour models demon-
strated superior efficacy for DHA–paclitaxel compared with
paclitaxel at equitoxic and equimolar doses. In a CD2F1 mouse/
M109 tumour model, DHA–paclitaxel caused complete regression
of 10 out of 10 tumours at its optimum dose (OD) of 120mgkg
 1
i.v. for 5 days. In contrast, no tumours were eliminated when
paclitaxel was given at its OD of 20mgkg
 1 (zero out of 10),
although slowing of tumour growth was seen. Similarly, in an HT-
29 human colon cancer model, three partial responses and two
complete responses were seen in five animals treated with DHA–
paclitaxel. In this experiment, paclitaxel induced only temporary
growth arrest (Bradley et al, 2001b).
The toxicity profile of DHA–paclitaxel was found to be superior
to that of paclitaxel in mouse, dog and rat models. Bradley et al
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lreported the maximum tolerated dose ratio of DHA–paclitaxel to
paclitaxel, based on taxane molarity, to be 4.4 for mice, 3.6 for rats
and 2.9 for dogs. No new toxicities were found for DHA–paclitaxel
compared to paclitaxel in these studies. In a mouse model, hind
limb paralysis seen with paclitaxel at its OD was not seen with
DHA-paclitaxel (Bradley et al, 2001b).
Bradley and co-workers have also reported the tumour, plasma
and muscle pharmacokinetics of DHA–paclitaxel in the M109
tumour-bearing mice. The AUC of DHA–paclitaxel in tumours
was found to be much higher than that of paclitaxel, and the time
during which tumour paclitaxel levels remained above a minimal
therapeutic level was much longer (240h compared to 16h)
(Bradley et al, 2001a).
Wolff and co-workers have reported the results of the first
human phase I study conducted at the Johns Hopkins Hospital. A
total of 24 patients were treated with DHA–paclitaxel over five
dose levels (200–1100mgm
 2). The drug was found to be well
tolerated with predictable toxicity and the dose-limiting toxicity
(DLT) of myelosuppression. No patient developed alopecia or
worse than grade 1 peripheral neuropathy. The pharmacokinetic
data mirrored that seen in animal studies; the half-life of DHA–
paclitaxel was found to be about seven times longer, the volume of
distribution 100 times smaller and the clearance 300 times slower
than paclitaxel. From this study the recommended dose for phase
II evaluation of the single agent was determined to be 1100mgm
 2
(Wolff et al, 2003).
Combinations of a taxane and a platinum-containing compound
are widely used in the treatment of many cancers (Harries and
Gore, 2002; Hussain and James, 2003; Montagut et al, 2003;
Ramalingam and Belani, 2002). The combination of DHA–
paclitaxel and carboplatin has the potential to be a regimen with
superior efficacy and less toxicity compared to currently used
combinations such as paclitaxel–carboplatin or docetaxel–carbo-
platin. In this phase I trial, we aimed to define the maximum
tolerated doses of the drugs when used in combination and to
characterise the toxicities of a DHA–paclitaxel and carboplatin
regimen.
PATIENTS AND METHODS
Patients
Patients were eligible for study entry if they fulfilled the following
criteria: a histological diagnosis of an advanced solid tumour; had
received conventional treatment for the disease; platinum-based
therapy was considered appropriate; at least 4 weeks and recovery
from previous antitumour therapy (6 weeks for Mitomycin-C and
nitrosoureas); age418 years; performance status 0, 1 or 2;
neutrophil count X1.5 10
9l; platelet count X100 10
9l;
adequate liver function (total bilirubin levels no greater than 1.5
times the normal limits and transaminases no higher than 2.5
times the normal limits); adequate renal function (glomerular
filtration rate (GFR)460mlmin
 1, as measured using 51Cr-
EDTA) and ability to give informed consent.
Exclusion criteria included prior therapy with any taxane; a past
or current history of other cancer (except for curatively treated
nonmelanoma skin cancer or carcinoma in situ of the cervix or
other cancers if no current evidence of active disease was present);
known or clinical evidence of central nervous system (CNS)
metastases; peripheral neuropathy (of any aetiology, which was
greater than grade 1); an unstable or serious concurrent medical
condition.
The study was approved by the local hospital ethics committees.
Study objectives
The primary objectives of the study were to assess the safety and
tolerability of DHA–paclitaxel and carboplatin when administered
in combination every 21 days, and to determine the maximum
tolerated doses of the combination in this patient population.
Treatment
Treatment was with 660mgm
 2 (starting dose) or 880mgm
 2
(second cohort) of DHA–paclitaxel administered intravenously
over a 2-hour period. At 20–30min following completion of
DHA–paclitaxel infusion, carboplatin was administered intrave-
nously over a period of 30min. Carboplatin was given at a dose of
AUC 5 (this dose was chosen as it is the commonly used dose of
carboplatin when given with paclitaxel) with glomerular filtration
rate determined by
51Cr-EDTA clearance. Treatment was adminis-
tered on day 1 and was followed by 20 days of observation.
Subsequent courses proceeded provided neutrophils were
41.5 10
9l
 1 and platelets 4100 10
9l
 1 on the day of
treatment. If on that day neutrophils and/or platelets had not
reached the above thresholds, then treatment was deferred until
recovery. Subsequent doses of DHA–paclitaxel were given with a
25% dose reduction. Likewise, if neutropenia associated with fever
and/or sepsis, or thrombocytopenia associated with bleeding had
occurred, then subsequent courses were given with a 25% dose
reduction in the DHA–paclitaxel.
If a DLT resulted from a nonhaematological toxicity, the next
DHA–paclitaxel dose treatment was reduced by one dose level. If
any nonhaematological toxicity of grade 2 or 3 (except alopecia,
and/or nausea, vomiting in patients who had not received optimal
treatment with antiemetics) was present on the day of scheduled
treatment, DHA–paclitaxel and carboplatin were withheld until
the adverse event was resolved to grade 1 or baseline level. If any
nonhaematological toxicity of grade 4 was present on the day of
scheduled therapy, the patient was to withdraw from further
participation in the study.
Treatment could continue for up to six courses or until evidence
of disease progression, intolerable adverse events, patient refusal
or investigator discretion. Tumour response was assessed every
two courses using the Response Evaluation Criteria in Solid
Tumors (RECIST). Safety parameters evaluated included adverse
events and laboratory evaluations including haematology, serum
biochemistry and urinalysis. Adverse events were graded accord-
ing to the NCI Common Toxicity Criteria, Version 2.0.
Dose escalation (Table 1)
The starting dose was DHA–paclitaxel 660mgm
 2 and carbopla-
tin AUC 5. Initially, three patients were treated at this dose level,
with the first patient being monitored for at least 2 weeks before
additional patients were treated. Escalation to a new level was
Figure 1 Molecular structure of DHA–paclitaxel.
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lpermitted when at least two of three patients had been evaluated
for 3 weeks.
Dose escalation was according to the standard phase I criteria.
Namely, if any patient experienced DLT that was considered to be
related to the therapy of DHA–paclitaxel and carboplatin (with the
exception of alopecia, and/or nausea or vomiting in patients who
had not received optimal antiemetic therapy), three additional
patients were enrolled at that dose level. Dose escalation then
continued with a total of six patients enrolled at each dose until the
recommended phase II dose level was reached. In the absence of
toxicity that would define the recommended phase II dose level,
drug dose levels were planned to be escalated as follows: Dose
Level 1 – carboplatin AUC 5, DHA–paclitaxel 660mgm
 2; Dose
Level 2 – carboplatin AUC 5, DHA–paclitaxel 880mgm
 2; Dose
Level 3 – carboplatin AUC 5, DHA–paclitaxel 1100mgm
 2 (not
reached).
Dose-limiting toxicity was defined as any one of the following
adverse events: (1) grade 4 hematological toxicity: grade 4
neutropenia lasting at least 7 days or neutropenia complicated
by fever or infection regardless of duration, thrombocytopenia
o25 10
9l
 1; (2) grade 3 or greater nonhaematological
toxicities including diarrhoea (except alopecia, and/or nausea,
vomiting in patients who had not received optimal treatment with
antiemetics); (3) grade 2 haemorrhage or neurological (cerebellar)
toxicities and (4) failure to recover from any drug-related toxicity
by day 22.
It was planned that additional patients could be entered at the
dose level at which escalation ceased, in order to better define the
safety profile for phase II studies. The recommended phase II dose
for the combination regimen was to be defined as the dose level at
which dose escalation for each compound was to cease, or a lower
dose, at the discretion of the Investigators.
RESULTS
Patients (Table 2)
Patient demographics are shown in Table 2. In total, 10 male and
five female patients entered the study (total 15) with a median age
of 59 years (range 33–71) and most (13 out of 15) with a baseline
ECOG performance status of 1. The commonest cancer diagnoses
were lung cancer and mesothelioma (five patients each), reflecting
the nature of the referral pattern to the phase 1 unit in our
institution. All patients had received prior chemotherapy and all
but one had received prior platinum-containing chemotherapy.
A total of 11 patients (73.3%) had received radiotherapy.
All patients had progressed on or following previous treatments
and no further conventional chemotherapy regimens were felt to
be appropriate.
The first patient was enrolled on 2 February 2001 and the last
patient came off study on 15 May 2002. All patients were evaluable
for safety and efficacy. Five (33.3%) patients went off-study for
disease progression. Four of the five patients had objective
measurement of progressive disease and one patient had sympto-
matic deterioration due to disease. Five (33.3%) patients were
removed from the study due to unacceptable toxicity, four patients
(26.7%) refused further treatment and one (6.7%) was removed by
decision of the investigators.
Drug administration, dose adjustments and dose delays
The three patients in cohort 1 received all treatment without dose
reduction or dose delay. Of the 12 patients in the second cohort,
nine required a dose reduction of DHA–paclitaxel to 660mgm
 2.
Six patients had the dose reduction after the first cycle. Five of the
12 patients (42%) had a delay of 1 week before delivery of the
second cycle due to failure of their blood count to recover by day
22. Three patients (25%) in the second cohort received all their
treatment at the planned dose of 880mgm
 2.
In total, 54 cycles of chemotherapy were delivered; 26 at a
DHA–paclitaxel dose of 660mgm
 2 and 28 at a dose of
880mgm
 2. At the DHA–paclitaxel dose of 880mgm
 2, a 1-week
dose delay for recovery of blood count was required in 30% of
cycles. In all, 14% of the cycles delivered at the DHA–paclitaxel
dose of 660mgm
 2 were delayed by 1 week (Table 3).
Toxicity
All 15 patients were evaluable for toxicity.
Dose-limiting toxicity (Table 1)
No DLT occurred in the first cohort of three patients initially
treated at the DHA–paclitaxel dose level of 660mgm
 2 and
carboplatin AUC 5.
Two of the first six patients of the second cohort (DHA–
paclitaxel 880mgm
 2 and carboplatin AUC 5) experienced
haematological DLTs in treatment course 1: grade 4 neutropenia
accompanied by fever; grade 3 thrombocytopenia and grade 4
neutropenia lasting 8 days. A third patient experienced the DLT of
grade 3 increased transaminases (transient and asymptomatic).
At this point dose escalation ceased, but it was decided to obtain
additional safety and toxicity data and to better define a
recommended phase II dose by recruiting a further six patients
at this dose level. Three of these six patients experienced DLTs in
course 1: grade 4 neutropenia greater than 7 days and grade 3
increased transaminases; grade 4 neutropenia lasting 12 days and
grade 3 increased transaminases; grade 4 neutropenia lasting eight
days and grade 3 increased transaminases.
Table 1 Dose escalation and dose limiting toxicity (DLT)
Dose level N
DHA-paclitaxel
(mgm
 2)
Carboplatin
AUC
Number of
patients with DLT
1 3 660 5 0 of 3
2 12 880 5 6 of 12
Table 2 Patient characteristics
Characteristic N
Entered/evaluable 15/15
Male/female 10/5
Median age (range) 59 (33–71)
ECOG
a performance status
01
11 3
21
Primary tumour site
Lung 5
Mesothelioma 5
Stomach 1
Oesophagogastric junction 1
Prostate 1
Unknown primary 1
Cervix 1
Previous chemotherapy regimens
00
11 1
2 or more 4
Prior platinum 14
Previous radiotherapy 11
Other treatment (vaccines, etc.) 2
aEastern Cancer Oncology Group.
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lHaematological toxicity
The haematological toxicities for the first course of carboplatin
and DHA–paclitaxel are listed in Table 4. None of the three
patients in the first cohort developed significant myelosuppres-
sion. Of the 12 patients in the second cohort treated with
carboplatin AUC 5 and DHA–paclitaxel 880mgm
 2, 11 developed
grade 3 or 4 neutropenia. For five patients, this was a DLT: four
patients with grade 4 neutropenia lasting for more than 7 days and
one further patient who developed neutropenic sepsis. One patient
developed grade 3 thrombocytopenia.
When evaluating all cycles of chemotherapy, in total 10 patients
experienced grade 4 neutropenia and three had an episode of
neutropenic sepsis (two at grade 4 neutropenia and one at
grade 3).
Nonhaematological toxicity
Of the second cohort of patients, dose-limiting nonhaematological
toxicity occurred in four patients in the first cycle of treatment,
three of whom also experienced dose-limiting haematological
toxicity. In all four cases, this was a short-lived asymptomatic
grade 3 rise of liver transaminases. This was not felt to be clinically
significant.
In subsequent courses, the worst nonhaematological toxicities
per patient are recorded in Table 5. Grade 3 fatigue was seen in
four patients. Grade 3 peripheral neuropathy occurred in one
patient, grade 2 in two patients and grade 1 neuropathy in a further
five.
Minimal alopecia was seen, with one patient developing grade 1
hair loss.
Tumour response
One patient had a partial response, 12 patients had stable disease
and two patients had progressive disease. The median time to
progression for the patients with stable disease from day 1 of the
first cycle of chemotherapy was 174 days (range 60–506 days).
The partial response occurred in a 59-year old man with
advanced moderately differentiated carcinoma of the oesophago-
gastric junction. Previously he had received two lines of
chemotherapy with cisplatin/5-flurouracil and ECF (epirubicin,
cisplatin and infusional 5-flurouracil). He had also received prior
radiotherapy. The patient completed six courses of study therapy
at a dose level of carboplatin AUC 5, DHA–paclitaxel 880mgm
 2.
A partial response was first documented by CT scan during course
2, and was confirmed after course 4 (6 weeks after first
documentation) and after course 6 (9 weeks after first documenta-
tion). During course 4, the patient experienced grade 3 para-
esthesia probably related to study medication. At the time of the
second confirmation of partial response (day 22 of course 6), the
paraesthesia was unresolved, and the patient withdrew from
the study due to this unacceptable toxicity. He subsequently
developed progressive disease at 142 days from the beginning of
chemotherapy.
DISCUSSION
In this study, we have demonstrated that the combination of
carboplatin and DHA–paclitaxel can be given to heavily pretreated
patients with advanced cancer with the DLTs of neutropenia and
transient transaminitis. Neutropenia appeared to be dose-related
with none of the three patients in the first cohort but five of the 12
patients treated at the dose level DHA–paclitaxel 880mgm
 2 and
carboplatin AUC 5 experiencing the DLT of neutropenia with the
first cycle. In one patient, this was an episode of neutropenic sepsis
and in the other four this was neutropenia lasting greater than 7
days (7, 8, 8 and 12 days). Neutropenia was the also the DLT seen
in the single-agent phase I study (Wolff et al, 2003).
In contrast, only one of the 12 patients in the second cohort
developed grade 3 thrombocytopenia. This suggests a possible
platelet-sparing effect of the DHA–paclitaxel–carboplatin combi-
nation as is seen with carboplatin–paclitaxel (Guminski et al,
2001; Pertusini et al, 2001). The transaminitis seen in this study
was short lived and asymptomatic. It is felt that this is unlikely to
be of clinical significance.
Grade 3 peripheral neuropathy was seen in one patient after four
courses of treatment in the same patient who had a partial
response to treatment. Further studies will need to monitor
peripheral neuropathy and in particular to determine if it is a
feature of prolonged treatment with DHA–paclitaxel as can be
seen with paclitaxel.
Fatigue was seen in several patients and is a feature of prolonged
chemotherapy with taxane-containing regimens. Given the small
sample size it is not possible to comment on whether the degree of
Table 3 Summary of drug administration and dose adjustments
DHA–paclitaxel dose level (mgm
 2) Number of patients
660 3
880-660 9
880 3
Total 15
DHA–paclitaxel dose level (mgm
 2)
Number of courses given at
dose level
660 26
880 28
Total 54
Note: -indicates DHA–paclitaxel dose reduction.
Table 4 Worst grade haematological toxicity first course
Grade
Dose level DHA–paclitaxel No of Pts. treated 0 1 2 3 4
Neutropenia
1 660 3 3 0 0 0 0
2 880 12 0 0 1 3 8
Thrombocytopenia
1 660 3 3 0 0 0 0
2 880 12 10 1 0 0 0
Pts¼patients.
Table 5 Nonhaematological toxicity worst course per patient
Grade
Toxicity 0 1 2 3 4
Nausea, vomiting 6 4410
Fatigue, weakness 3 0840
Hypersensitivity 14 1000
Transaminases 10 0050
Neuropathy 7 5210
Alopecia 14 1000
Skin 13 2000
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lfatigue seen in this study is above that one would expect for
standard carboplatin/paclitaxel in this population.
The lack of alopecia is of great interest. The carboplatin–
paclitaxel combination is standard treatment for women with
advanced ovarian cancer. Hair loss in these women is often a
major cause for concern and may lead some women to refuse
treatment with taxanes. A regimen with equivalent toxicity but no
alopecia would have significant advantages for many patients.
Although too few patients were treated on this study to
comment on efficacy, the one partial response and 10 patients
with stable disease was encouraging. The 6 month median time to
progression seen in the patients with stable disease was also of
interest. Further phase II studies of the combination in specific
tumour types are required to more accurately estimate the true
response rate.
We conclude that the recommended dose for further study in
pretreated patients should be DHA–paclitaxel 660mgm
 2 and
carboplatin AUC5 given on a 3-weekly basis. In addition, we
believe this combination to be of sufficient interest to warrant
testing in previously untreated patients, for example with non-
small lung cancer. In such a chemotherapy-naı ¨ve population,
consideration should be given to testing a 4-weekly regimen of
DHA–paclitaxel 880mgm
 2 and carboplatin AUC 5. However, as
such patients were not included in this study, such a trial would
require a dose-validating phase with careful monitoring of
haematological toxicity.
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